Published in J Exp Med on May 16, 2005
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med (2009) 2.51
Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther (2009) 2.44
NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest (2008) 2.29
PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest (2006) 2.11
Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest (2013) 2.08
Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov (2009) 2.01
Opposing functions of IKKbeta during acute and chronic intestinal inflammation. Proc Natl Acad Sci U S A (2008) 1.90
IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol (2008) 1.76
RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci U S A (2008) 1.68
Cutting edge: NLRP12 controls dendritic and myeloid cell migration to affect contact hypersensitivity. J Immunol (2010) 1.59
RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest (2008) 1.52
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 1.51
Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nat Med (2016) 1.46
Role of NF-κB in the skeleton. Cell Res (2010) 1.45
Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron (2014) 1.44
Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res Ther (2005) 1.43
Inflammation-activated protein kinases as targets for drug development. Proc Am Thorac Soc (2005) 1.40
Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol (2009) 1.39
NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci U S A (2013) 1.35
DNA damage drives accelerated bone aging via an NF-κB-dependent mechanism. J Bone Miner Res (2013) 1.31
IL-1β-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKKβ. Nat Immunol (2010) 1.27
Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci (2010) 1.21
Novel functions for NFκB: inhibition of bone formation. Nat Rev Rheumatol (2010) 1.19
Regulation of NFATc1 in Osteoclast Differentiation. J Bone Metab (2014) 1.15
NF-κB signaling and bone resorption. Osteoporos Int (2013) 1.11
WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. Am J Pathol (2008) 1.09
TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis. Mol Cell Biol (2012) 1.05
Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J Biol Chem (2008) 1.02
IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res (2010) 1.02
IκB kinase β regulates epithelium migration during corneal wound healing. PLoS One (2011) 1.00
A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway. Database (Oxford) (2011) 0.99
Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther (2011) 0.97
Signaling Pathways in Osteoclast Differentiation. Chonnam Med J (2016) 0.94
NF-κB-Mediated Regulation of Osteoclastogenesis. Endocrinol Metab (Seoul) (2015) 0.92
Etiopathogenesis of mandibulofacial and maxillofacial abscesses in mice. Comp Med (2010) 0.92
M-CSF induces monocyte survival by activating NF-κB p65 phosphorylation at Ser276 via protein kinase C. PLoS One (2011) 0.88
Receptor activator of nuclear factor-κB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice. Hepatology (2012) 0.88
Constitutively active canonical NF-κB pathway induces severe bone loss in mice. PLoS One (2012) 0.88
Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis. J Cell Biochem (2009) 0.87
NF-kappaB functions in stromal fibroblasts to regulate early postnatal muscle development. J Biol Chem (2009) 0.85
IKK{beta} as a target for treatment of inflammation induced bone loss. Ann Rheum Dis (2005) 0.85
Inflammation, cancer, and bone loss. Curr Opin Pharmacol (2009) 0.85
Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde? Arthritis Res Ther (2015) 0.84
Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss. Sci Rep (2015) 0.83
Osteopetrosis in TAK1-deficient mice owing to defective NF-κB and NOTCH signaling. Proc Natl Acad Sci U S A (2014) 0.83
Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway. Mol Cancer Res (2010) 0.82
Tyrosine phosphorylation is required for IkappaB kinase-beta (IKKbeta) activation and function in osteoclastogenesis. J Biol Chem (2010) 0.82
p62 is required for stem cell/progenitor retention through inhibition of IKK/NF-κB/Ccl4 signaling at the bone marrow macrophage-osteoblast niche. Cell Rep (2014) 0.82
Mx1-cre mediated Rgs12 conditional knockout mice exhibit increased bone mass phenotype. Genesis (2013) 0.81
Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. Br J Pharmacol (2012) 0.81
Osteoimmunology - Unleashing the concepts. J Indian Soc Periodontol (2011) 0.81
Evidence that the kinase-truncated c-Src regulates NF-κB signaling by targeting NEMO. J Cell Biochem (2011) 0.80
RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Adv Drug Deliv Rev (2011) 0.80
NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases. Adv Protein Chem Struct Biol (2016) 0.78
RANKL signaling and osteoclastogenesis is negatively regulated by cardamonin. PLoS One (2013) 0.78
Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling. Int J Cancer (2011) 0.78
Protective protein/cathepsin A down-regulates osteoclastogenesis by associating with and degrading NF-kappaB p50/p65. J Bone Miner Metab (2008) 0.78
TRP14 inhibits osteoclast differentiation via its catalytic activity. Mol Cell Biol (2014) 0.77
Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo. Arthritis Res Ther (2006) 0.77
Water extract of Spatholobus suberectus inhibits osteoclast differentiation and bone resorption. BMC Complement Altern Med (2013) 0.77
Constitutive activation of IKK2/NF-κB impairs osteogenesis and skeletal development. PLoS One (2014) 0.76
Inflammatory osteolysis: a conspiracy against bone. J Clin Invest (2017) 0.76
Loss of IκB kinase β promotes myofibroblast transformation and senescence through activation of the ROS-TGFβ autocrine loop. Protein Cell (2016) 0.75
Sirt6 cooperates with Blimp1 to positively regulate osteoclast differentiation. Sci Rep (2016) 0.75
IKKβ in postnatal perichondrium remotely controls endochondral ossification of the growth plate through downregulation of MCP-5. Cell Death Differ (2014) 0.75
Effects of a GSK-3β inhibitor on the renal expression levels of RANK, RANKL and NF-κB in a rat model of diabetic nephropathy. Exp Ther Med (2016) 0.75
(-)-Epicatechin 3-O-β-D-allopyranoside prevent ovariectomy-induced bone loss in mice by suppressing RANKL-induced NF-κB and NFATc-1 signaling pathways. BMC Complement Altern Med (2017) 0.75
OCLI-023, a Novel Pyrimidine Compound, Suppresses Osteoclastogenesis In Vitro and Alveolar Bone Resorption In Vivo. PLoS One (2017) 0.75
WITHDRAWN: Cardamonin Inhibits Osteoclastogenesis Induced by Tumor Cells Through Interruption of the Signaling Pathway Activated by Receptor Activator of NF-κB Ligand. Cancer Lett (2011) 0.75
Carboxyl terminus of Hsp70-interacting protein regulation of osteoclast formation in mice through promotion of tumor necrosis factor receptor-associated factor 6 protein degradation. Arthritis Rheumatol (2014) 0.75
Regulation by Phloroglucinol of Nrf2/Maf-Mediated Expression of Antioxidant Enzymes and Inhibition of Osteoclastogenesis via the RANKL/RANK Signaling Pathway: In Silico study. Acta Inform Med (2015) 0.75
c-Rel is dispensable for the differentiation and functional maturation of M cells in the follicle-associated epithelium. Immunobiology (2016) 0.75
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Inducible gene targeting in mice. Science (1995) 21.22
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 14.89
NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature (1997) 11.31
Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell (1995) 9.11
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem (1995) 8.32
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science (2001) 7.66
Reaching a genetic and molecular understanding of skeletal development. Dev Cell (2002) 7.55
Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature (1993) 7.10
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol (2001) 6.73
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science (1994) 5.97
Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science (1999) 5.95
NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell (2001) 5.88
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med (1997) 5.72
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med (1995) 5.27
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A (1990) 4.40
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE (1999) 3.79
Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev (1999) 3.41
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32
The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature (2004) 3.18
Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet (1999) 3.17
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science (2001) 3.11
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell (2001) 3.10
Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med (2004) 2.94
The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med (2003) 2.20
Bone destruction in arthritis. Ann Rheum Dis (2002) 2.15
Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem (2001) 2.13
Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res (2000) 1.95
IKK beta is required for peripheral B cell survival and proliferation. J Immunol (2003) 1.92
Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol (1997) 1.88
Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem (2000) 1.49
Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect Immun (1999) 1.47
Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology (1996) 1.12
Progressive increase in bone mass and development of odontomas in aging osteopetrotic c-src-deficient mice. Bone (2000) 0.99
Solution structure of N-TRADD and characterization of the interaction of N-TRADD and C-TRAF2, a key step in the TNFR1 signaling pathway. Mol Cell (2000) 0.90
Immunity, inflammation, and cancer. Cell (2010) 28.27
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
The pathogenesis of rheumatoid arthritis. N Engl J Med (2011) 12.16
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98
AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 8.47
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
Reaching a genetic and molecular understanding of skeletal development. Dev Cell (2002) 7.55
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science (2006) 7.35
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Inflammation and colon cancer. Gastroenterology (2010) 6.32
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13
Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell (2006) 5.97
Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38
JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 5.38
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18
Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 5.08
A validated regulatory network for Th17 cell specification. Cell (2012) 4.82
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 4.68
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature (2002) 4.44
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
"Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med (2008) 4.38
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest (2012) 4.31
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell (2004) 4.28
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
The molecular clock mediates leptin-regulated bone formation. Cell (2005) 3.88
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell (2004) 3.71
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med (2005) 3.70
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51
The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell (2008) 3.35
Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33
The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron (2004) 3.33
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature (2004) 3.18
IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12
Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J Biol Chem (2001) 3.10
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 3.09
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08